Microdosing a GLP-1 in perimenopause or menopause: what is known, and what is not

The 30-second summary

• Microdosing GLP-1 medicines in midlife has not been studied. There are no trials of doses below the licensed ones, and none of any dose for menopause symptoms such as hot flushes, sleep or mood.
• The known risks come from how people do it: pens not designed to give part-doses, compounded vials and unregulated peptides. In perimenopause you can also still become pregnant.
• What is well supported is less glamorous: protect muscle and bone with protein and strength training, get proper help for symptoms, and make any dose decision with a prescriber.

Why this question is everywhere

The years around the menopause change the body in ways many women find hard. In the SWAN study, which followed women through the menopause transition with body scans, the rate of fat gain doubled at the start of the transition while lean mass began to fall, and both trends continued until about 2 years after the final period. The NHS says weight gain at this time is common and often settles around the stomach and upper body.

Into that gap has stepped a lot of marketing for "microdosing": small doses of tirzepatide or semaglutide, sold as a gentler way to calm appetite, lift energy or ease symptoms. The idea is appealing. The evidence has not caught up with it.

What "microdosing" usually means

Online, microdosing usually means taking less than the licensed doses, either from compounded vials or by counting clicks on a branded pen to deliver part of a dose. That is different from a prescriber keeping someone on a lower licensed dose, which the prescribing information allows for when side effects are a problem. (See staying on a lower GLP-1 dose and GLP-1 microdosing.)

What the evidence covers

Microdoses: nothing yet. A search of PubMed finds no randomised trial of microdosed GLP-1 medicines, in midlife women or anyone else. What has been published is commentary, including a 2026 report for nurse practitioners describing dosing errors and safety risks from manipulating pens, using compounded vials and buying illicit "research-grade" peptides.

Full doses in menopause: limited. A 2026 position statement from the Spanish Menopause Society reviewed the evidence for these medicines in peri- and postmenopausal women. It found that semaglutide has the most menopause-specific evidence, but that this evidence "remains limited and largely observational", and that tirzepatide is promising but still needs menopause-specific evaluation.

A lower licensed dose: one trial. In SURMOUNT-MAINTAIN, adults who dropped from 10 or 15 mg of tirzepatide to 5 mg for a year kept off less weight than those who stayed on their full dose, though more than those who stopped. Almost two-thirds of participants were women, with an average age of 46.6, but the trial did not look at menopause specifically.

What it does not do, as far as anyone knows

There is no evidence that GLP-1 medicines, at any dose, treat hot flushes, night sweats, sleep problems or menopausal low mood. We could find no trial of them for those symptoms.

One published case points the other way. A 51-year-old woman taking oral oestrogen for hot flushes found they worsened, along with her mood, while her semaglutide dose was being increased. When the dose increases were slowed, the symptoms settled. The author suggested that slower stomach emptying may have reduced how well the oral oestrogen was absorbed during dose increases. It is a single case and proves nothing, but it is a reason to tell your doctor if your menopause symptoms change after starting or increasing a GLP-1.

For the symptoms themselves, the NHS lists HRT as the main treatment, with cognitive behavioural therapy and other medicines as options for hot flushes when HRT is not suitable or not wanted. (See GLP-1 medicines and the menopause and perimenopause.)

The risks that come from how people microdose

Pens are built for whole doses. Mounjaro's prescribing information says each KwikPen contains 4 doses of 0.6 ml, that anything left over should be thrown away, and that its instructions must be followed carefully. It gives no instructions for delivering part of a dose by counting clicks.

Compounded vials are not the licensed product. They are not made or checked in the same way, and the FDA has acted against them in the United States. (See compounded semaglutide and tirzepatide and the FDA's action on compounded GLP-1s.)

"Research-grade" peptides are not medicines at all. They are sold outside any regulated supply chain.

Four things specific to midlife

You can still get pregnant in perimenopause. The NHS says menopause is only confirmed once you have gone 12 months without a period while not using hormonal contraception, and that HRT is not contraception. Mounjaro's prescribing information advises switching from the pill to a non-oral method, or adding condoms, for 4 weeks after starting and after each dose increase. If you are planning a pregnancy, the labels advise stopping semaglutide at least 2 months beforehand and tirzepatide at least 1 month beforehand. (See GLP-1 medicines and birth control.)

HRT and GLP-1s together. The Spanish Menopause Society statement says the reported link between HRT and greater weight loss on semaglutide is only hypothesis-generating, and should not be used as a reason to start HRT to boost weight loss. If you take both, make sure both prescribers know.

Bones. The NHS advises calcium-rich foods such as milk, yoghurt and kale, and weight-bearing exercise, to protect bones through the menopause. It is worth knowing that in the SELECT trial of semaglutide, more hip and pelvis fractures were reported in women on semaglutide than on placebo: 1.0% against 0.2%. (See bone density on a GLP-1.)

Muscle. Menopause pushes lean mass down, and a 2025 joint advisory from four US nutrition and obesity medicine societies notes that rapid weight loss on GLP-1 medicines frequently includes muscle as well as fat. The Spanish Menopause Society statement stresses resistance exercise and adequate protein for women using these medicines. (See keeping muscle on a GLP-1 and protein on a GLP-1.)

If you are considering it

Rather than improvising a dose, take these questions to a prescriber:

1. Would a licensed dose, including staying longer on a lower step, meet the same goal?
2. What contraception do I need while I am still having periods?
3. How does this fit with my HRT, or with other treatment for my symptoms?
4. What should I do about bone and muscle, and should anything be checked?
5. How will we judge whether it is working, and what is the plan if it is not?

What to do with this

Protein matters more in midlife, not less. The calculator asks about your cycle, including whether you still have periods, and works out your protein floor alongside your calorie target and an estimate of how much you are likely to manage at a licensed dose.

Get your numbers

Sources

1. Greendale GA, et al. Changes in body composition and weight during the menopause transition. JCI Insight 2019. PubMed
2. Sánchez-Prieto M, et al. Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. Maturitas 2026. PubMed
3. Parker AE. Worsening vasomotor symptoms in the setting of estradiol and semaglutide: a case report. Menopause 2025. PubMed
4. Trainer N. The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. J Am Assoc Nurse Pract 2026. PubMed
5. Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026. PubMed
6. Mounjaro KwikPen solution for injection in pre-filled pen: Summary of Product Characteristics. electronic medicines compendium. emc
7. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen: Summary of Product Characteristics. electronic medicines compendium. emc
8. NHS. Menopause and perimenopause. nhs.uk
9. NHS. Treatment for menopause and perimenopause. nhs.uk
10. NHS. Things you can do for menopause and perimenopause. nhs.uk
11. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars 2025. PubMed

Medical disclaimer: Articles in the foodose research library are educational, not medical advice. Do not change or split doses of any medicine without your prescriber. See our full medical disclaimer.